thought call
thought perform solid face valu
adjust ep guidanc increas today call like littl reassur investor
concern long-term growth humira concentr risk notabl
bright spot ou humira consensu suggest
worst part eros curv may higher level better ou humira
legaci portfolio drive margin predict earn growth
admittedli impress y/i view main uncertainti
beyond hc polici chang us continu trajectori newer
asset skyrizi venclexta orilissa etc imbruvica hcv
perform modestli inde yet break sale orilissa
new franchis skyrizi risankizumab upadacitinib face strong competit
dynam see skyrizi us approv unlik address humira overhang
recent call former pbm execut highlight challeng
sequenc humira behind skyrizi upadacitinib variou market see
 takeaway biosimilar kol call
suspect import launch overal think greater visibl
need non-humira product portfolio reduc concentr risk
absenc transform bd continu see littl upsid reiter ew
pipelin updat nda upadacitinib accept decis anticip
fda also review snda venclexta cll regulatori submiss
elagolix uterin fibroid imbruvica cll plan later year
phase sc levodopa/ carbidopa deliveri system initi
model chang follow call updat revenu
forecast respect
adjust adjust ep estim
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
larg behind us due settlement
less concern futur
franchis pipelin beyond core
product interest like success
unsur enough make revenu
come introduct humira biosimilar
pipelin success multipl asset indic
would drive revenu thu share price upsid
lessen impact humira biosimilar could also
wors expect impact humira biosimilar
entrant competit prior amgevita
failur pipelin asset could also hamper long-term
million except per share itemspriorcurrentpriorcurrenthumira non-oper incom ep barclay abbvi inc
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
